";s:4:"text";s:6347:" Zomedica Pharmaceuticals Corp. operates as a development stage veterinary diagnostic and pharmaceutical company. These price ends are 354.55% and +354.55% off the current price level respectively, although investors could be excited at the prospect of a +354.55% if the ZOM share price touches on the median price of $0.5.Let’s briefly compare Zomedica (ZOM) stock to its peers. Estimates by analysts give the company expected earnings per share (EPS) of $0, with the EPS growth for the year raised at -$0.03 for 2020 and -$0.02 for next year. We use cookies and browser capability checks to help us deliver our online services, including to learn if you enabled Flash for video or ad blocking. The average price target for the stock over the next 12 months is $0.5, with the estimates having a low of $0.5 and a high of $0.5. This represents a 2.6% Short interest in Shares outstanding on August 13, 2020. Looking at the stock we see that its previous close was $0.12 and the beta (5Y monthly) reads … at $1.52 per share.Derivative/Non-derivative trans. Zomedica Pharmaceuticals Corp. (AMEX: ZOM) shares are -67.16% down in the year-to-date (YTD) period and have moved -9.19% or -$0.01 lower in the latest trading session. Zomedica Pharmaceuticals Corp. (NYSE:ZOM) traded at $0.11 at last check on 8/31/2020, making a downturn move of -9.19% on its previous day’s price.Looking at the stock we see that its previous close was $0.12 and the beta (5Y monthly) reads -0.2 with the day’s price range being $0.1070 – 0.1175. The RSI (14) is pointing at 22.75 while the volatility over the past week is 7.72% and drops to 5.87% over the past one month. The Zoom initial public offering in April 2019 raised $752 million, with shares priced at 36. Shares short rose in August from the previous month at 10.61 Million. at $1.52 per share.Derivative/Non-derivative trans. It plans to offer novel diagnostics and innovative therapeutics... Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements.
The data shows that short shares as of August 13, 2020, stood at 14.67 Million at a short ratio of 0.34. Zomedica Pharmaceuticals (NYSEMKT:ZOM) initiates public offering of common stock. Investors are also buoyed by the number of investors in a company, with LexinFintech Holdings Ltd. having a total of 159 institutions that hold shares in the company. With this in place, we can see that the company’s diluted EPS inclined $0.30 on the year-over-year period, growing to $0.50 as given in the last earnings report.In terms of the balance sheet & cash flow as of (Sep 2020), the total assets figure advanced to $3.1 billion from $2.86 billion over the previous quarter. at $1.2 per share. In terms of its 52-week price range, ZOM has a high of $0.5 and a low of $0.11. Current shares outstanding are 564.05 Million.According to data from Thomson Reuters, insiders hold 38.45% of the company’s shares while institutions hold 9.67%. View zom business summary and other industry information. SAN JOSE, Calif., April 17, 2019 (GLOBE NEWSWIRE) -- Zoom Video Communications, Inc. (“Zoom”) today announced the pricing of its initial public offering of 20,869,565 shares of Class A common stock at a price to the public of $36.00 per share. However, stock’s trailing 12-month performance remains nearly +1.59% lower. The company has a 12-month trailing PE ratio of 0. We find that today’s price change of -9.19% and -70.45% over the past 12 months for ZOM competes that of Zoetis Inc Cl A (ZTS), which has seen its stock price rise 0.06% in the latest trading session and is +26.64% over the last one year. The company’s stock has gained about -31.25% over that past 30 days.Zomedica has a market cap of $63.32 Million and is expected to release its quarterly earnings report on August 10, 2020. Zomedica Pharmaceuticals Corp. company facts, information and stock details by MarketWatch. Wall Street estimates earnings per share to be at an average of -$0.02 for the next year.According to SEC data, total insider shares purchases at the company stands at 0 over the last 12 months, while SEC filings reveal that there have been 0 insider sales over the same period. The forecasts give the Zomedica Pharmaceuticals Corp. stock a price target range of $0.50 on the higher side while at least one analyst think the stock could plunge to a low of $0.50.
Analysts predict that the stock will reach $12.75 and spell out a more modest performance – a 38.75% return. This represented a 80.37% of the company’s total revenues which amounted $418.68 million. Zoetis has a P/E ratio of 47.35 compared to Zomedica’s 0 and Takeda’s 22.93. The shares were bought at $0.16 per share.LexinFintech Holdings Ltd. (NASDAQ:LX), on the other hand, is trading around $7.81 with a market cap of $1.45B and analyst research firms have a positive stance on its shares.
Trade ZOM stock for free with recommended broker TD Ameritrade. The top two institutional holders are Goldman Sachs Group, Inc. with over 5.08 million shares worth more than $54.07 million. 9,911,434 of the shares are being offered by Zoom and 10,958,131 of the shares are being offered by certain selling stockholders. SeeThruEquity Initiates Coverage on Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) with a Price Target of $3.24 ACCESSWIRE -6.90% Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It has $29 million cash and only $1.45 million debt. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the ZOM stock to lose ahead of the earnings release.
ZOM has 6 good things going for it: 1. Comparatively, the stock is -78.22% down YTD and -32.90% over the trailing 3-month period. These figures represent -0.84% and at -0.33% growth in EPS for the two years respectively.On the other hand, looking at the outlook for the ZOM stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 100% Sell. ZM stock popped 72% on the first day of trading.
Recent Comments